Biogen (BIIB) insider Priya Singhal plans 2,660-share stock sale on NASDAQ

Rhea-AI Filing Summary

Biogen insider Priya Singhal has filed a notice to sell company stock. The filing covers a proposed sale of 2,660 shares of Biogen common stock through Fidelity Brokerage Services LLC on 02/09/2026, listed on NASDAQ, with an aggregate market value of 531,547.80.

The shares to be sold come from recent restricted stock vesting awards. She acquired 1,963 shares on 02/06/2026 and 697 shares on 02/07/2026, both described as compensation from the issuer. In the past three months, she also sold 748 common shares on 02/02/2026 for gross proceeds of 134,116.40.

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK
Filer CCC
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer

SEC File Number

Address of Issuer

Phone

Name of Person for Whose Account the Securities are To Be Sold

See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

Relationship to Issuer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common	Fidelity Brokerage Services LLC 900 Salem Street Smithfield RI 02917	2660	531547.80	146758528	02/09/2026	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common	02/06/2026	Restricted Stock Vesting	Issuer			1963	02/06/2026	Compensation
Common	02/07/2026	Restricted Stock Vesting	Issuer			697	02/07/2026	Compensation

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Name and Address of Seller	Title of Securities Sold	Date of Sale	Amount of Securities Sold	Gross Proceeds
Priya Singhal 225 Binney Street Cambridge MA 02142	Common	02/02/2026	748	134116.40

144: Remarks and Signature

Remarks

Date of Notice

Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1

ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

FAQ

What does the latest Form 144 filing reveal about Biogen (BIIB)?

The filing shows insider Priya Singhal plans to sell 2,660 Biogen common shares with an aggregate market value of 531,547.80 on 02/09/2026. These shares relate to recently vested restricted stock compensation awards from the company.

How many Biogen (BIIB) shares is Priya Singhal planning to sell?

Priya Singhal plans to sell 2,660 Biogen common shares through Fidelity Brokerage Services LLC. The filing lists an aggregate market value of 531,547.80 for this planned transaction, with NASDAQ named as the securities exchange for the sale.

How did Priya Singhal acquire the Biogen (BIIB) shares she plans to sell?

The planned sale involves shares acquired via restricted stock vesting from Biogen. She received 1,963 shares on 02/06/2026 and 697 shares on 02/07/2026, both categorized as compensation from the issuer rather than cash purchases on the open market.

Has Priya Singhal sold Biogen (BIIB) shares recently before this notice?

Yes. During the past three months, she sold 748 Biogen common shares on 02/02/2026, generating gross proceeds of 134,116.40. The new Form 144 filing discloses an additional planned sale beyond that earlier transaction.

On which exchange and through which broker will the Biogen (BIIB) shares be sold?

The notice states that the 2,660 Biogen common shares are to be sold on NASDAQ. The broker handling the planned transaction is Fidelity Brokerage Services LLC, located at 900 Salem Street, Smithfield, RI 02917, according to the filing details.

How many Biogen (BIIB) shares are outstanding compared to this planned sale?

The filing reports 146,758,528 Biogen common shares outstanding. The planned sale of 2,660 shares by insider Priya Singhal is small relative to this total, representing only a minor fraction of the company’s outstanding equity base.